Search Patents
  • MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20150344523
    Abstract: The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: May 5, 2015
    Publication date: December 3, 2015
    Inventors: Kaycie Deyle, Blake Farrow, James R. Heath
  • Peptide inhibitors of Akt and uses thereof
    Publication number: 20030181366
    Abstract: The subject invention relates to peptide inhibitors of Akt as well as to uses of these inhibitors. More specifically, the inhibitors may be used, for example, to induce apoptosis in cells and sensitize tumor cells to cancer therapies. The peptides may also be used to purify Akt.
    Type: Application
    Filed: March 21, 2002
    Publication date: September 25, 2003
    Inventors: Yan Luo, Vincent L. Giranda, Paul L. Richardson, Richard A. Smith
  • Inhibitors of Akt activity
    Patent number: 8614221
    Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: December 24, 2013
    Assignees: Merck Sharp & Dohme Corp., MSD K.K.
    Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
  • Akt and regulation of RA synovial fibroblast apoptosis
    Publication number: 20060104951
    Abstract: The administration of an Akt inhibitor in a suitable carrier to a rheumatoid arthritis synovial fibroblast affords a process for inducing rheumatoid arthritis synovial fibroblast apoptosis. The Akt inhibitor is administered either as an active molecule or as a gene sequence expressible within rheumatoid arthritis synovial fibroblast cells. The gene sequence can be encompassed within a gene vector such as an adenovirus. A process for assaying rheumatoid arthritis drug candidates for apoptosis affect includes exposing a culture of rheumatoid arthritis synovial fibroblast cells to a drug candidate and monitoring apoptosis in the culture in the presence of the drug candidate. Apoptosis in the culture is compared to apoptosis induced in a duplicate culture in the presence of a known Akt inhibitor.
    Type: Application
    Filed: November 16, 2004
    Publication date: May 18, 2006
    Inventors: John Mountz, Huang-Ge Zhang, Hui-Chen Hsu
  • Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
    Publication number: 20020169126
    Abstract: The invention provides E1A gene based anti-cancer therapy that targets cancers and tumors involving phospho-Akt expression (and/or Akt activation) and/or phospho-p38 downregulation (and/or p38 inactivation).
    Type: Application
    Filed: March 21, 2002
    Publication date: November 14, 2002
    Inventors: Mien-Chie Hung, Yong Liao
  • Methods and Compositions for Modulating AKT3
    Publication number: 20200390884
    Abstract: Compounds and compositions for selectively modulating Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Application
    Filed: August 10, 2020
    Publication date: December 17, 2020
    Inventors: Samir N. KHLEIF, Mikayel MKRTICHYAN, Iryna LEBEDYEVA, Thomas ALBERS
  • Inhibitors of AKT/PKB with anti-tumor activity
    Patent number: 8183249
    Abstract: The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering all effective amount of a compound of formula I to the person or animal.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: May 22, 2012
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Mei Sun, Said M. Sebti
  • COMPOUND AS AKT KINASE INHIBITOR
    Publication number: 20230357242
    Abstract: Provided is a compound as an Akt kinase inhibitor. The present invention specifically relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating Akt kinase-related diseases.
    Type: Application
    Filed: September 30, 2021
    Publication date: November 9, 2023
    Inventors: Yinsheng ZHANG, Yong GAO, Wei SHI, Damin ZHAO, Yuan YIN
  • AKT INHIBITOR
    Publication number: 20220144821
    Abstract: The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the use thereof in prevention and/or treatment of a disease mediated by AKT protein kinase.
    Type: Application
    Filed: January 22, 2020
    Publication date: May 12, 2022
    Inventors: Changyou Ma, He Tian, Jie An, Jianliang Zhao, Donghui Chen, Jian Wu, Dan Xu, Chunxia Zhu, Zhoushan Tian
  • Methods and compositions for inhibiting Akt3
    Patent number: 10342868
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: July 9, 2019
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Methods and compositions for inhibiting Akt3
    Patent number: 10159731
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 25, 2018
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE
    Publication number: 20230039099
    Abstract: Relapse in adoptive cell transfer of CAR-T cells is often the result of CAR-T cells disappearance. Disclosed herein a method for enhancing CAR-T cell therapy in a subject, comprising administering to a subject undergoing adoptive cell transfer of therapeutic CAR-T cells an Akt inhibitor in an amount effective to increase the persistence of the CAR-T cells. As a consequence, a subject treated with a combination of CAR-T cells and an Akt inhibitor is less likely to relapse. Therefore, also disclosed herein is a method for treating a subject, comprising adoptively transferring to the subject an effective amount of a composition comprising a CAR-T cell, and administering to the subject an Akt inhibitor in an amount effective to increase the persistence of the CAR-T cells.
    Type: Application
    Filed: November 18, 2020
    Publication date: February 9, 2023
    Inventors: Marco L. Davila, Said M. Sebti
  • MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20180072772
    Abstract: The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: August 17, 2017
    Publication date: March 15, 2018
    Inventors: Kaycie Deyle, Blake Farrow, James R. Heath
  • Methods and compositions for inhibiting Akt3
    Patent number: 10588966
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 17, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY
    Publication number: 20130034598
    Abstract: The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal.
    Type: Application
    Filed: May 21, 2012
    Publication date: February 7, 2013
    Inventors: Jin Q. Cheng, Mei Sun, Said M. Sebti
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20130072500
    Abstract: The present invention provides compounds of Formula I including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.
    Type: Application
    Filed: November 14, 2012
    Publication date: March 21, 2013
    Applicant: ARRAY BIOPHARMA INC.
    Inventor: Array BioPharma Inc.
  • Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex
    Publication number: 20100173928
    Abstract: In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity.
    Type: Application
    Filed: July 15, 2008
    Publication date: July 8, 2010
    Inventors: David M. Sabatini, Dos D. Sarbassov, Michael Andreeff, Marina Konopleva, Zhihong Zeng, Francis J. Giles
  • Inhibitors of AKT Activity
    Publication number: 20110288090
    Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: January 25, 2010
    Publication date: November 24, 2011
    Inventors: Donna J. Armstrong, Yasuhiro Goto, Takashi Hashihayata, Tetsuya Kato, Michael J. Kelly, III, Mark E. Layton, Craig W. Lindsley, Yoshio Ogino, Yu Onozaki, Kenvin J. Rodzinak, Michael A. Rossi, Philip E. Sanderson, Jiabing Wang, Melissa M. Yaroschak
  • Methods and compositions for modulating Akt3 activity
    Patent number: 10980878
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: April 20, 2021
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva, Thomas Albers
  • ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS
    Publication number: 20130096144
    Abstract: The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the activity of Akt including, for example, cancer and other diseases.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicant: Incyte Corporation
    Inventor: Incyte Corporation
Narrow Results

Filter by US Classification